Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASF-1057 cream dose-comparison study in seborrhoeic dermatitis
2006-005637-37Phase 2Completed
- Sponsor
- Astion Pharma
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of nicotinamide, monoctanoin and ASF-1057 in seborrheic dermatitis (SD) (4 arms), sponsored by Astion Pharma. Primary endpoint: Number of treatment responders at day 21. Started Dec 2006; status: completed.
02
Drugs
nicotinamidemonoctanoinASF-1057
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on 2006-005637-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005637-37.